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Abstract
Pulmonary hypertension (PH) is a common complication of advanced chronic obstructive pulmonary disease (COPD) and is defined 
by a mean pulmonary artery pressure (PAP) ≥ 25 mm Hg at rest in the supine position. Owing to its frequency, COPD is a common 
cause of PH; in fact, it is the second most frequent cause of PH, just after left heart diseases. PH is due to the elevation of pulmonary 
vascular resistance, which is caused by functional and morphological factors, chronic alveolar hypoxia being the most important. 
In COPD PH is generally mild to moderate, PAP usually ranging between 25 and 35 mm Hg in a stable state of the disease. 
A small proportion of COPD patients may present a severe or “disproportionate” PH with a resting PAP > 35–40 mm Hg. The 
prognosis is particularly poor in these patients. In COPD PH worsens during exercise, sleep and severe exacerbations of the 
disease, and these acute increases in afterload may favour the development of right heart failure. 
The diagnosis of PH relies on Doppler echocardiography, and right heart catheterization is needed in a minority of patients. 
Treatment of PH in COPD relies on long-term oxygen therapy (≥ 16h/day) which generally stabilizes or at least attenuates 
the progression of PH. Vasodilator drugs, which are commonly used in idiopathic pulmonary arterial hypertension, have rarely 
been used in COPD, and we lack studies in this field. Patients with severe PH should be referred to a specialist PH centre 
where the possibility of inclusion in a controlled clinical trial should be considered.
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pulmonary hypertension
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Introduction 
Chronic obstructive pulmonary disease 
(COPD) is a major cause of morbidity and mortality 
worldwide, with an increasing prevalence in recent 
years [1]. One well-known complication of COPD is 
pulmonary hypertension (PH), a condition that was 
denominated “cor pulmonale” in the past [2–4]. 
In the updated WHO classification of pul-
monary hypertension [5] PH secondary to COPD 
is placed in group 3, i.e. PH associated with lung 
diseases and/or hypoxemia (Tab. 1). Owing to its 
frequency COPD is by far the most common cause 
of PH in this group, far more common than inter-
stitial lung disease and obesity-hypoventilation 
syndrome. When considering the five groups of 
classification, COPD is the most frequent cause of 
PH just after PH secondary to left heart disease. 
With time, PH may lead to the development of right 
ventricular enlargement, which may result in right 
ventricular failure, but it should be emphasized 
that PH is only one among other complications of 
advanced COPD and that the prognosis of COPD 
is linked to the severity of respiratory insufficien-
cy rather than to the occurrence of PH, which is 
essentially a “marker” of long-standing hypoxa-
emia [6]. Indeed, this does not apply to severe or 
“disproportionate” PH, but very few COPD patients 
exhibit this severe form of PH [7]. 
This review article gives an overview of PH 
resulting from COPD and tries to cover all aspects 
from epidemiology to treatment. 
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> 20 mm Hg, ranges from 35% to more than 90% 
[7, 13, 17–19]. In the studies conducted by Scharf et 
al. [19], Thabut et al. [13] and Chaouat et al. [7], 5%, 
13.5% and 5.8%, respectively, of the COPD patients 
had severe PH (PAP > 35 or 40 mm Hg). 
To our knowledge, the only population-based 
study that aimed to determine the prevalence of 
subjects in the general population at risk of deve-
loping PH (i.e. markedly hypoxemic subjects with 
severe COPD) is that of Williams and Nicholl [20]. 
They estimated that in Sheffield (UK) 0.3% of adu-
lts aged ≥ 45 years were at risk. Extrapolating for 
England and Wales, this would represent 60,000 
subjects. However, these data were obtained more 
than 20 years ago, whereas the incidence and 
prevalence of COPD have markedly increased in 
recent years. The prevalence of COPD is estimated 
to be approximately 5% in the adult population in 
most European countries [21], and 6% of COPD pa-
tients have severe or very severe disease and are at 
risk of PH [12]; this would represent approximately 
1.5 million patients for Europe. 
Pathology
The structural basis of PH in COPD includes 
three potential mechanisms: remodelling, reduction 
in the total number of pulmonary vessels, and pul-
monary thrombosis. However, the only demonstrated 
morphological basis is the remodelling of the pulmo-
nary arteries and arterioles. Remodelling includes 
muscularization of pulmonary arterioles (< 80 µm) 
which can extend to the periphery in precapillary 
vessels (20 µm), and changes in the intima: intimal 
thickening is observed in muscular pulmonary ar-
teries and in pulmonary arterioles [22, 23]. These 
intimal lesions are characterized by the development 
of longitudinal muscle and fibrosis. The other com-
ponent of intimal thickness is the occurrence of inner 
muscular tubes, i.e. a new layer of circular smooth 
muscle sandwiched between internal and external 
lamina in pulmonary arterioles [24]. 
It has been known for many years that pulmonary 
vascular remodelling is present not only in advanced 
COPD, but also in patients with mild COPD [25, 26]. 
It has been shown in recent years that smokers with 
normal lung function may develop intimal thicke-
ning in pulmonary muscular arteries [26]. These 
structural abnormalities could be the consequence 
of endothelial dysfunction of pulmonary arteries, 
probably induced by cigarette smoke [26]. However, 
the clinical relevance of these early abnormalities is 
presently unknown, and it should be emphasized 
that they have been observed in smokers and in mild 
COPD patients not exhibiting PH. 
Definitions 
The current definition of PH is a resting mean 
pulmonary artery pressure (PAP) measured by right 
heart catheterization (RHC) ≥ 25 mm Hg [8, 9]. It is 
accepted that normal PAP is between 8 and 20 mm 
Hg [8–10]. In the past, PH complicating chronic re-
spiratory disease was generally defined by a resting 
PAP > 20 mm Hg [11], which is slightly different from 
the present definition of PH [8, 9] and is explained 
by the fact that a resting PAP > 20 mm Hg was con-
sidered as being abnormal, even in elderly subjects. 
These various definitions should be kept in mind 
when comparing studies, particularly in terms of 
prevalence of PH in COPD [12].
Severe PH in COPD could be defined by a PAP 
> 35 [13] or > 40 mm Hg [7] in patients investigated 
at rest during a stable state of the disease. In fact, the-
re is no consensual definition of severe PH in COPD. 
In the “natural history” of COPD PH is often 
preceded by an abnormally large increase in PAP 
during exercise [14], generally defined by a mean 
pressure > 30 mm Hg for a mild level of exercise. 
The term “exercising” pulmonary hypertension has 
been used, but we believe that the term pulmonary 
hypertension should be reserved to resting PH [4].
Prevalence of PH in COPD 
Determination of the prevalence of PH in 
COPD has been impeded by difficulties in ob-
taining valid data from an adequate sample of 
COPD patients. The main reason is that right heart 
catheterization (RHC), the gold standard for the 
diagnosis of PH, cannot be performed on a large 
scale in COPD patients for ethical reasons, and Dop-
pler echocardiography, which is the best noninvasive 
method [15], is often inaccurate in COPD [16]. 
Only studies from hospital-based samples are 
presently available, but they have no real epidemio-
logic value. The prevalence of PH, defined by PAP 
Table 1.  Group 3 of the present classification of pulmona-
ry hypertension.  Pulmonary hypertension due to 
lung disease and/or hypoxia
3.1 Chronic obstructive pulmonary disease (COPD)
3.2 Interstitial lung disease 
3.3 Other pulmonary diseases
3.4 Sleep disordered breathing
3.5 Alveolar hypoventilation disorders
3.6 Chronic exposure to high altitude 
3.7 Developmental abnormalities
Adapted from Simonneau et al. [5]
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Mechanisms of PH in COPD 
PAP represents the sum of the pulmonary ar-
tery “capillary” (wedge) pressure (PCWP), which 
is equivalent to the left atrial pressure (LAP), and 
of the driving pressure across the pulmonary cir-
culation (DP). The latter is the product of cardiac 
output ( ) and pulmonary vascular resistance 
(PVR). Accordingly, 
PAP = PCWP (or LAP) + DP
PAP = PCWP + × PVR
Thus, three variables can contribute to an 
elevation of PAP: wedge pressure, cardiac output 
and pulmonary vascular resistance. In COPD the 
role of an elevated cardiac output is almost ne-
gligible. An abnormally elevated wedge pressure 
has been observed in a relatively high percentage 
of COPD patients in some studies [19, 27]. Ho-
wever, many of these patients had an associated 
left heart disease [19, 27]. One hypothesis is that 
the increase in intrathoracic pressure in emphy-
sematous patients may induce an increase in 
PCWP. This has been frequently observed during 
exercise [28] and has been attributed to dynamic 
hyperinflation [29]. 
Actually, at rest and during a steady state of 
the disease, PCWP is most often normal in COPD 
patients not exhibiting associated significant left 
heart disease. Thus, in COPD PH is precapillary, 
almost exclusively accounted for by the increased 
PVR [4, 30]. 
The factors leading to an increased PVR in 
COPD are numerous, but alveolar hypoxia is the 
predominant one [31]. Two distinct mechanisms 
of action of alveolar hypoxia must be considered: 
acute hypoxia causes pulmonary vasoconstriction, 
and chronic hypoxia induces, with time, structural 
changes in the pulmonary vascular bed, i.e. remo-
delling of the pulmonary vasculature [32]. 
Acute alveolar hypoxia induces a rise of PVR 
and PAP in humans as well as in almost all spe-
cies of mammals that is accounted for by hypoxic 
pulmonary vasoconstriction (HPV) [33, 34]. HPV 
is observed in normal subjects [34] as well as in 
patients with chronic respiratory disease [35]. 
This vasoconstriction is localized in the resistan-
ce pulmonary arteries (< 500 µm) and its precise 
mechanism is now better understood. In particu-
lar, there has been a marked improvement of the 
knowledge of smooth muscle cell potassium chan-
nels involved in the regulation of the pulmonary 
vascular tone [36] and of the endothelium-derived 
mediators [37]. 
In normal humans the reactivity of the pul-
monary circulation to acute hypoxia varies from 
one individual to another and this interindividual 
variability is also found in COPD patients [38], but 
the potential clinical consequences of this variabi-
lity are presently unknown. The situations which 
bear the closest analogy with acute hypoxic chal-
lenges are severe exacerbations of COPD leading to 
acute respiratory failure [39] and the sleep-related 
episodes of worsening hypoxaemia [40]. 
Chronic alveolar hypoxia induces, in healthy 
people living at altitudes > 3500 m, précapillary 
PH similar to that observed in COPD [41], and 
morphological studies have shown remodelling of 
the pulmonary vascular bed. There is some degree 
of similarity between these structural changes and 
those observed in COPD patients with PH, and it 
is accepted that chronic alveolar hypoxia is the 
main cause of pulmonary vascular remodelling in 
COPD, even though one morphological study led 
to different conclusions [22].
Chronic alveolar hypoxia is not the only factor 
leading to elevated PVR. Patients with advanced 
COPD have marked morphological changes of the 
lung (including loss of capillaries and reduction 
of the pulmonary vascular bed), particularly when 
emphysema is severe, and these changes could 
partly account for the increased PVR [19, 22]. 
It has been hypothesized that inflammation 
of the pulmonary arteries could contribute to pul-
monary vascular remodelling in COPD, and to the 
elevation of PVR [42]. However, few studies have 
confirmed this hypothesis [43]. It has also recently 
been shown that systemic inflammation increases the 
risk of developing PH in COPD [44, 45]. The issue 
of the role of inflammation in PH complicating 
COPD remains controversial [46].
Finally, the occurrence and the degree of seve-
rity of PH in COPD could be modulated by genetic 
factors, as suggested by recent studies [47, 48]. 
More studies are needed in this field. 
Diagnosis of PH in COPD 
Symptoms and physical signs are of little help 
in the diagnosis of PH. Dyspnoea is generally pre-
sent in advanced COPD patients with and without 
PH. Dyspnoea is the consequence of airflow limita-
tion and pulmonary hyperinflation rather than PH.
Physical signs occur late, being observed 
at an advanced stage of the disease far after the 
development of PH. Peripheral (ankle) oedema is 
the best sign of right heart failure (RHF), but it is 
not specific and can arise from other causes [49]. 
In some patients with PH it does not occur at all. 
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A murmur of tricuspid regurgitation, suggesting 
right ventricular dilatation, is rarely present in 
COPD patients, which can be explained by the mild 
to moderate degree of PH in most COPD patients. 
The sensitivity of the electrocardiogram (ECG) 
for the diagnosis of PH is poor (20–40%) whereas 
the specificity of signs of right ventricular hyper-
trophy is high [50]. A normal ECG does not exclude 
the presence of PH in COPD patients. The radio-
logical prediction of PH is even more problematic 
since radiological signs lack both sensitivity and 
specificity [50]. 
Magnetic resonance imaging is probably the 
best method for the measurement of right ventri-
cular ejection fraction [51], right ventricular mass 
and the diameter of the pulmonary artery, but its 
role in the diagnosis strategy of PH in COPD is not 
well established. 
Doppler echocardiography is by far the best 
method for the noninvasive diagnosis of PH [15]. 
The maximum velocity of the tricuspid regurgi-
tation jet allows the calculation of the right ven-
tricular to right atrial gradient according to the 
Bernouilli equation. The gradient is added to right 
atrial pressure (5 or 10 mm Hg) to give an estimated 
value of right ventricular systolic pressure that is 
equal to pulmonary artery systolic pressure. With 
the same technique (continuous wave Doppler 
echocardiography) it is possible, in cases of pul-
monary regurgitation, to estimate the pulmonary 
artery diastolic pressure. 
However, in COPD the chance of obtaining 
tricuspid regurgitation signals of sufficient quality 
is generally low [52]. In the large series (n = 374) of 
candidates for lung transplantation (most of them 
being COPD) investigated by Arcasoy et al. [16] the 
estimation of systolic PAP was possible in only 44% 
of the patients, and 52% of pressure estimations 
were found to be inaccurate when compared with 
pressures measured during RHC (> 10 mm Hg 
difference). In a recent study [53] the bias of 
Doppler echocardiography in the measurement of 
systolic PAP compared with RHC was 2.8 mm Hg 
(95% CI: –18.7–24.0 mm Hg), which is high when 
one takes into account the modest level of PH in 
most COPD patients. 
Systolic PAP can also be estimated from Dop-
pler pulmonary flow velocity curves since the 
correlations between systolic PAP and the time to 
peak pulmonary blood velocity (acceleration time 
measured by pulsed Doppler echocardiography) 
are strong [54]. To our knowledge, the evaluation 
of right ventricular dysfunction with the Tei index 
and the tricuspid annular displacement has not 
been performed in COPD patients [12].
Plasma brain natriuretic peptide could be 
a biomarker of PH in chronic lung diseases [55], 
but studies are needed to determine whether it is 
a useful diagnostic tool in COPD patients. 
RHC continues to be the gold standard for 
the diagnosis of PH [18, 30]. It allows the direct 
measurement of PAP, PCWP, right heart filling 
pressures, and cardiac output by thermodilution 
or according to Fick’s principle. Measurements 
are performed at rest in the supine position and can 
be obtained during steady-state exercise and after 
therapeutic interventions (O2, NO and other vasodi-
lators). PVR is calculated according to the formula: 
PVR = PAP – PCWP, where is the cardiac output. 
                   The major drawback of RHC is indeed its 
invasive nature. The procedure has some risks 
and can not be performed on a large scale in COPD 
patients. Furthermore, there is no evidence-based 
study demonstrating its clinical value in advanced 
COPD [12]. Therefore, RHC can not be used routinely. 
In COPD patients, Doppler echocardiography 
must be performed when PH is suspected (patients 
with chronic hypoxaemia, severe and very severe 
COPD, i.e. stages 3 and 4 of the GOLD classifica-
tion). The indications of RHC should be limited 
to the cases where there is a suspicion of severe 
PH (systolic pressure estimated from Doppler 
echocardiography > 50–60 mm Hg). RHC can help 
to differentiate diastolic left heart failure from 
precapillary PH in COPD since it allows the me-
asurement of capillary (wedge) pressure (PCWP). 
Accordingly, RHC may be useful for prescribing 
the most appropriate treatment. 
Characteristics of PH in COPD
PH is precapillary with an increased pressure 
difference between PAP and PCWP reflecting the 
increased PVR (Fig. 1). In almost all COPD patients 
marked oscillations of systolic and diastolic pul-
monary pressure are observed with respiration 
(Fig. 1). These oscillations reflect the elevated 
intrathoracic pressure changes due to increased 
airway resistance.
The main characteristic of PH in COPD is 
probably its mild to moderate degree, with resting 
PAP in a stable state of the disease usually ranging 
between 20–25 and 35 mm Hg [14, 18]. This mo-
dest degree of PH, also observed in other chronic 
respiratory diseases [56, 57], is very different from 
other causes of PH, such as chronic pulmonary 
thromboembolic disease (CTEPH) and in parti-
cular idiopathic pulmonary arterial hypertension 
(IPAH) in which PAP is usually > 40 mm Hg and 
may exceed 80 mm Hg in some patients. Table 2 
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[59]. It can be seen that PH is severe in IPAH (mean 
PAP of 56 mm Hg) and in CTEPH (46 mm Hg) but 
is rather mild in COPD (26 mm Hg), as well as in 
IPF (24 mm Hg) and in OHS (26 mm Hg). 
In COPD, when PH occurs, PVR is moderately 
increased and cardiac output is in the normal 
range, contrasting with IPAH and CTEPH (Tab. 2). 
A PAP > 40 mm Hg is unusual in COPD patients, 
except when they are investigated during an acute 
exacerbation [4] or when there is an associated 
cardiopulmonary disease [7]. The consequences 
of the modest level of PH include the absence or 
late occurrence of RHF. However, PH, even if mild 
at baseline, may worsen during exercise, sleep and 
acute exacerbation of the disease [4]. 
PAP increases markedly during steady state 
exercise in COPD patients with resting PH [4, 17, 60], 
as illustrated in Figure 2, which shows that in 
these patients’ (Group 3) PAP rises from a mean 
of 27 to 55 mm Hg during a 30–40 watt exercise 
of 7–10 min. duration. This is explained by the 
fact that PVR does not decrease during exercise in 
these patients whereas it does in healthy subjects. 
Acute increases of PAP during sleep have been 
observed in COPD patients with respiratory failure 
[40]. They are principally observed in REM sleep, 
during which dips in oxygen saturation are more 
severe. These episodes are not caused by apnoeas, 
except if COPD is associated with a sleep apnoea 
syndrome, but by alveolar hypoventilation and/or 
ventilation-perfusion mismatching [40]. PAP can 
increase by > 10 mm Hg from its baseline value [4]. 
In patients with advanced COPD severe exa-
cerbations can lead to acute respiratory failure 
characterized by a worsening of hypoxaemia and 
Table 2.  Comparison of pulmonary hypertension in chronic hypoxic lung disease (COPD, IPF, OHS) to idiopathic pulmonary 
arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH)
COPD IPF OHS Idiopathic PAH CTEPH
References 18 56 57 58 59
Number of patients 62 31 36 259 500
Age (years) 55 ± 8 58 ± 16 62 ± 12 50 –
FEV1 [mL] 1170 ± 390 1655 ± 650 1610 ± 600 – –
FEV1 (% of predicted) – – – > 70 –
PaO2 [mm Hg] 60 ± 9 68 ± 12 59 ± 8 – –
PaCO2 [mm Hg] 45 ± 6 35 ± 5 50 ± 4 – –
PAP [mm Hg] 26 ± 6 24 ± 11 26 ± 10 56 46
PCPW [mm Hg] 8 ± 2 7 ± 4 – 8 –
[L/min/m²] 3.8 ± 1.1 3.4 ± 0.8 2.9 ± 0.9 2.3 2.2
Mean values ± standard deviation. COPD — chronic obstructive pulmonary disease; FEV1 — forced expiratory volume in 1 second; IPF — idiopathic pulmonary fibrosis; 
OHS — obesity–hypoventilation syndrome; PAP — pulmonary artery mean pressure; PCWP — pulmonary capillary wedge pressure;  — cardiac output
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Figure 1. Resting and exercising pulmonary artery mean pressure 
(PAP) in a large series of chronic obstructive pulmonary disease 
patients. Group 1: resting PAP < 20 mm Hg and exercising PAP 
< 30 mm Hg. Group 2: resting PAP < 20 mm Hg and exercising PAP 
> 30 mm Hg. Group 3: resting PAP > 20 mm Hg (personal data) 
compares the pulmonary haemodynamic data of 
COPD patients exhibiting PH [18], a series of pa-
tients with idiopathic pulmonary fibrosis (IPF) [56] 
and obesity-hypoventilation syndrome (OHS) [57], 
a series of patients with IPAH (French Registry) 
[58], and a series of CTEPH from San Diego (USA) 
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hypercapnia. In patients exhibiting PH there is a si-
multaneous increase of PAP from its baseline value 
[39]. PAP may increase by as much as 20 mm Hg 
but usually returns to baseline after recovery [4]. 
The striking parallel between changes in PaO2 and 
PAP suggests the presence of hypoxic pulmonary 
vasoconstriction. 
Thus, even though PH is usually mild to mo-
derate in COPD patients, it may increase markedly 
during exercise, sleep and exacerbations of the di-
sease; these acute increases of afterload, especially 
during exacerbations, can favour the development 
of RHF [49].
Severe and “out of proportion” PH in COPD 
As mentioned previously, PH in COPD is usu-
ally mild to moderate with a resting PAP ranging 
between 20 and 35 mm Hg. A minority of COPD 
patients exhibit severe PH, which can be defined by 
resting PAP > 35 mm Hg [13, 19] or > 40 mm Hg 
[7]. This level of PH is considered to be “out 
of proportion” in COPD patients investigated 
during a stable state of the disease, and recent 
studies have aimed to evaluate its frequency and 
understand its mechanisms [7, 13]. Chaouat et 
al. [7] observed that from 998 COPD patients 
investigated, when clinically stable with right 
heart catheterization performed between 1990 
and 2002, only 27 had resting PAP ≥ 40 mm Hg. 
Of the 27 patients, 16 had an associated disease 
that could explain in part the severity of PH: 
4 had a left heart disease responsible for an 
increased PCWP and a decreased left ventricu-
lar ejection fraction; 2 patients had CTEPH; and 
6 had an associated restrictive lung disease (mainly 
severe obesity plus obstructive sleep apnoeas). In 
these 6 latter patients PaO2 was very low (44 ± 
± 4 mm Hg), with a further decrease during sleep. 
Finally, just 11 patients had COPD as the only cause 
of severe PH [7]. In view of these results, it must be 
recommended that the presence of an associated di-
sease should be investigated in COPD patients with 
severe PH. This severe PH is uncommon in COPD 
(1.1% of the patients investigated) [7]. Table 3 
indicates that these patients have less severe 
bronchial obstruction than COPD patients with 
“usual” PH, and their mean FEV1 was 50% of the 
predicted value; they had profound hypoxaemia 
and exhibited hypocapnia. 
Thabut et al. [13] identified, by statistical analy-
sis, a similar subgroup of 16 patients with moderately 
severe bronchial obstruction contrasting with severe 
PH. The patients of Thabut et al. [13] and Chaouat 
et al. [7] with severe PH represent a subset of COPD 
patients in whom pulmonary vascular disease is 
predominant. Actually, some characteristics of these 
patients (low cardiac output, hypocapnia, low DLCO) 
are similar to those observed in idiopathic PAH. Due 
to the severity and the scattered number of COPD 
patients with severe (or “out of proportion”) PH, 
these patients should be referred to an expert centre 
of pulmonary vascular disease so that RHC can be 
performed, and they should be included in registries 
and clinical trials [8]. 
Table 3.  Comparison of COPD patients with severe (PAP > 
40 mm Hg) pulmonary hypertension to patients with 
usual pulmonary hypertension (PAP 20–40 mm Hg)
Variables Severe PH without 
associated  
disease (n = 11)
Usual PH  
(n = 16)
Age (years) 67 (62–68) 66 (63–73)
FEV1 (% predicted) 50 (44–56) 27 (23–34)
FEV1/VC (%) 49 (39–53) 34 (26–38)
DLCO [mL/min/mm Hg] 4.6 (4.2–6.7) 10.3 (8.9–12.8)
PaO2 [mm Hg] 46 (41–53) 56 (54–64)
PaCO2 [mm Hg] 32 (28–37) 47 (44–49)
A–aO2 [mm Hg] 56 (50–68) 30 (27–37)
PAP [mm Hg] 48 (46–50) 25 (22–37)
PCWP [mm Hg] 6 (4–7) 7 (6.5–7.5)
[L/min/m²] 2.3 (1.8–2.5) 2.8 (2.4–3.1)
TPR [IU/m²] 21.3 (17.6–36.6) 9.0 (7.4–9.9)
A–Ao2 — alveolar arterial PO2 difference; DLCO — diffusion capacity for carbon 
monoxide; FEV1 — forced expiratory volume in 1 second; PAP — pulmonary artery 
mean pressure; PCWP — pulmonary capillary wedge pressure; PH — pulmonary 
hypertension; TPR — total pulmonary resistance; VC — vital capacity. Values are 
median (interquartile range). Adapted from Chaouat et al. [7]
30
5
Figure 2. In chronic obstructive pulmonary disease (COPD) pul-
monary hypertension is “precapillary”: the pulmonary “capillary” 
wedge pressure (left part of the trace) is normal (5 mm Hg), 
whereas pulmonary artery mean pressure (right part of the tra-
ce) is elevated (30 mm Hg) owing to the elevation of pulmonary 
vascular resistance. In COPD patients, important swings of sys-
tolic and diastolic pulmonary artery pressure from inspiration to 
expiration are observed, which reproduce the elevated intratho-
racic pressure changes 
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Evolution and prognosis of pulmonary  
hypertension in COPD
The “natural history” of PH in COPD is not 
fully understood [14], but several studies have 
shown that the progression of PH is generally slow 
and that PAP may remain stable over periods of 
2 to 5 years [61, 62]. In a study in which 93 patients 
were followed-up for 5–12 years, the changes in 
PAP were rather small: + 0.5 mm Hg/year for the 
group as a whole [63]. Nevertheless, a minority of 
advanced COPD patients exhibit a marked worse-
ning of PAP during follow-up [63]. These patients 
are characterized by a progressive deterioration 
of PaO2 and PaCO2 during the follow-up [62, 63]. 
A study on the “natural history” of pulmonary ha-
emodynamics in COPD patients with an initial PAP 
< 20 mm Hg showed that only 33 of 121 developed 
PH (PAP > 20 mm Hg) after a mean interval of 6.8 ± 
± 2.9 years [14]. 
Does PH lead, with time, to RHF? Peripheral 
oedema are frequently observed in advanced COPD 
patients and are considered to reflect RHF, but the 
possible occurrence of RHF in these patients has 
been questioned [64], particularly because the de-
gree of PH is most often mild in COPD. Peripheral 
oedema may simply indicate the presence of se-
condary hyperaldosteronism induced by functional 
renal insufficiency and is not synonymous with 
heart failure [3, 64]. 
The role of pressure overload (i.e. pulmonary 
hypertension) in the development of RHF in these 
patients has been debated. It has been denied by 
MacNee et al. [65], but another study from our 
group [49] has led to different conclusions: in 9 of 
16 patients with marked peripheral oedema during 
an exacerbation of COPD, haemodynamic signs of 
RHF were present during the episode of oedema 
and were probably accounted for by a significant 
worsening of PH (from 27 ± 5 to 40 ± 6 mm Hg, 
p < 0.001) which, in turn, was explained by 
a worsening of hypoxemia. Thus, many patients 
with advanced COPD will never develop RHF; 
however, some patients will experience episodes 
of “true” RHF during exacerbations of the disease 
accompanied by a worsening of PH [49] (Tab. 4).
The level of PAP is a good indicator of pro-
gnosis in COPD (18,66). The prognosis is worse in 
patients with PH compared with patients without 
PH [18, 66] and is particularly poor in patients 
with severe PH, including patients with dispropor-
tionate PH [7]. The 5-year survival rate of COPD 
patients with PH (PAP > 20 mm Hg) is about 50% 
[18, 66], but these results were obtained before the 
era of long-term oxygen therapy (LTOT), which 
significantly improves the prognosis of markedly 
hypoxaemic patients, most of them exhibiting PH 
[67, 68]. Of interest is that PAP remains an excel-
lent prognostic indicator in COPD patients treated 
with LTOT [6]. 
Treatment of pulmonary hypertension  
in COPD
The treatment of PH in COPD is based on 
LTOT. This raises the important question as to 
whether it is necessary to treat PH in COPD with 
methods other than LTOT. PH, even if modest in 
most patients, may worsen during acute exacer-
bations, and these acute increases in PAP may 
contribute to the development of RHF [62]. This 
could represent an argument for the treatment of 
PH, which must be also considered in all cases of 
severe PH (PAP > 35–40 mm Hg). 
Long-term oxygen therapy 
Alveolar hypoxia is considered to be the major 
determinant of the elevation of PVR and PAP in 
COPD patients. Accordingly, LTOT is a logical tre-
atment of PH in COPD. The well-known Nocturnal 
Oxygen Therapy Trial (NOTT) [67] and Medical 
Research Council (MRC) study [69] were not prin-
cipally devoted to pulmonary haemodynamics, but 
RHC was performed at the onset in all patients and 
Table 4.  Evolution of arterial blood gases and haemodynamic variables before (T1) and during (T2) an episode of peripheral 
oedema in severe COPD patients
RVEDP [mm Hg] PAP [mm Hg]  [l/min/m²] PaO2 [mm Hg] PaCO2 [mm Hg]
T1 T2 T1 T2 T1 T2 T1 T2 T1 T2
Group 1 
(n = 9)
7.5 ± 3.9 13.4 ± 1.2* 27 ± 5 40 ± 6* 3.23 ± 0.82 3.19 ± 1.07 63 ± 4 49 ± 7* 46 ± 7 50 ± 14*
Group 2 
(n = 7)
5.5 ± 2.4 5.1 ± 1.5 20 ± 6 21 ± 5 3.63 ± 0.36 3.29 ± 1.32 66 ± 7 59 ± 7 42 ± 6 45 ± 6
PAP — pulmonary artery mean pressure;   — ardiac output; RVEDP — right ventricular end–diastolic pressure. T1 — stable state of the disease; T2 — episode of oedema. 
Group 1 — patients with haemodynamic signs of right heart failure (elevated RVEDP); group 2 — patients without haemodynamic signs of right heart failure.  
Values are mean ± SD. Adapted from Weitzenblum et al. [49] 
*Difference between T1 and T2 statistically significant, p < 0.001
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follow-up dates were available for a relatively high 
number of patients. In the MRC study [68] LTOT 
patients had a stable PAP after one year whereas 
control patients had a significant increase in PAP. 
In the NOTT study [67] continuous LTOT (≥ 18 h/ 
/day) slightly but significantly decreased resting 
and exercising PAP after 6 months whereas noc-
turnal LTOT (10–12 h/day) did not. 
Further studies more specifically devoted to 
the pulmonary haemodynamic evolution under 
LTOT [69, 70] have shown either a tendency to-
wards the reversal of the progression of PH [69] or 
a stabilization of PH under LTOT [70] over periods 
of two to six years. However, PAP seldom returned 
to normal. It must be emphasized that the best 
haemodynamic results have been obtained in stu-
dies in which the daily duration of LTOT was the 
longest (≥ 16–18 h/day) [67, 69]. Accordingly, one 
should recommend continuous oxygen therapy.
Vasodilator drugs 
Experience with vasodilators (prostanoids, 
endothelin receptors antagonists, phosphodieste-
rase 5 inhibitors) has come from the treatment of 
IPAH. It is tempting to use these drugs in cases of 
PH complicating COPD, particularly in the (rare) 
cases of severe (“disproportionate”) PH. Unfortuna-
tely, there have been very few studies in this field. 
In the only (to our knowledge) controlled study in 
which COPD patients with mild resting PH or no 
resting PH at all received bosentan or placebo, the 
results were disappointing and included a worse-
ning of hypoxaemia [71], which is a well-known 
deleterious effect of vasodilators in COPD. 
Nitric oxide is a selective and potent pulmona-
ry vasodilator. One long-term study (3 months) in 
40 patients already on LTOT showed that the ad-
dition of nitric oxide produced significant improve-
ment in PAP, PVR and cardiac output [72]. However, 
the technological and toxicological problems related 
to the prolonged use of inhaled NO are far from being 
solved, and, to our knowledge, inhaled NO is not 
used at present in stable COPD patients. 
It is presently recommended not to treat COPD 
patients with drugs dedicated to IPAH outside 
of trials and to refer patients with severe PH to 
a regional specialist PH centre [8]. 
Finally, single-lung transplantation could be 
considered in COPD patients with severe PH aged 
< 65 years and without severe comorbidities [12], 
but we lack studies in this field [73].
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